Cue Operating Income vs Tax Provision Analysis

CUE Stock

USD 1.09 0.07 6.86%

Cue Biopharma financial indicator trend analysis is way more than just evaluating Cue Biopharma prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Cue Biopharma is a good investment. Please check the relationship between Cue Biopharma Operating Income and its Tax Provision accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cue Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.

For information on how to trade Cue Stock refer to our How to Trade Cue Stock guide.

Operating Income vs Tax Provision

Operating Income vs Tax Provision Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Cue Biopharma Operating Income account and Tax Provision. At this time, the significance of the direction appears to have very strong relationship.

The correlation between Cue Biopharma's Operating Income and Tax Provision is 0.87. Overlapping area represents the amount of variation of Operating Income that can explain the historical movement of Tax Provision in the same time period over historical financial statements of Cue Biopharma, assuming nothing else is changed. The correlation between historical values of Cue Biopharma's Operating Income and Tax Provision is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Operating Income of Cue Biopharma are associated (or correlated) with its Tax Provision. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Tax Provision has no effect on the direction of Operating Income i.e., Cue Biopharma's Operating Income and Tax Provision go up and down completely randomly.

Correlation Coefficient

0.87

Relationship Direction	Positive
Relationship Strength	Strong

View All Relationships

Operating Income

Operating Income is the amount of profit realized from Cue Biopharma operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Cue Biopharma is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.

Tax Provision

The amount set aside by a company to cover any estimated taxes for the current period. It reflects the company's expected tax liabilities.

Most indicators from Cue Biopharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cue Biopharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cue Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.

For information on how to trade Cue Stock refer to our How to Trade Cue Stock guide.At present, Cue Biopharma's Sales General And Administrative To Revenue is projected to drop slightly based on the last few years of reporting.

	2022	2023	2024	2025 (projected)
Interest Income	928.2K	2.7M	3.1M	3.2M
Net Interest Income	214.4K	1.4M	1.6M	1.7M

Interest Income Net Interest Income

Cue Biopharma fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Deferred Long Term Liab	Property Plant And Equipment Gross	Total Current Assets	Common Stock
Total Assets		0.33	0.88	0.98	0.66	0.97	0.9	-0.9	-0.79	0.76	0.96	0.91	0.87	0.86	0.99	0.86	0.57	0.49	0.77	0.91	0.82	0.88	0.83	0.85	1.0	0.83
Other Current Liab	0.33		0.49	0.21	0.35	0.41	0.37	-0.03	-0.71	0.73	0.26	0.41	0.49	0.52	0.29	0.63	0.66	0.16	0.65	0.24	0.71	0.58	0.4	0.47	0.31	0.66
Total Current Liabilities	0.88	0.49		0.79	0.49	0.94	0.88	-0.72	-0.91	0.86	0.86	0.91	0.92	0.95	0.84	0.95	0.84	0.3	0.79	0.87	0.9	0.97	0.73	0.88	0.86	0.95
Total Stockholder Equity	0.98	0.21	0.79		0.68	0.93	0.84	-0.94	-0.68	0.67	0.96	0.84	0.78	0.76	0.98	0.75	0.43	0.48	0.66	0.87	0.73	0.78	0.82	0.77	0.99	0.72
Other Liab	0.66	0.35	0.49	0.68		0.65	0.38	-0.65	-0.36	0.48	0.62	0.42	0.5	0.49	0.65	0.49	0.15	0.48	0.41	0.49	0.42	0.49	0.93	0.32	0.69	0.47
Net Tangible Assets	0.97	0.41	0.94	0.93	0.65		0.87	-0.89	-0.84	0.82	0.98	0.88	0.85	0.87	0.96	0.91	0.7	0.35	0.74	0.87	0.86	0.91	0.85	0.85	0.97	0.9
Property Plant And Equipment Net	0.9	0.37	0.88	0.84	0.38	0.87		-0.71	-0.86	0.76	0.83	1.0	0.93	0.92	0.85	0.88	0.69	0.43	0.84	0.9	0.85	0.91	0.62	0.98	0.87	0.85
Net Debt	-0.9	-0.03	-0.72	-0.94	-0.65	-0.89	-0.71		0.54	-0.55	-0.96	-0.7	-0.62	-0.62	-0.91	-0.63	-0.35	-0.25	-0.42	-0.77	-0.59	-0.64	-0.78	-0.62	-0.92	-0.6
Retained Earnings	-0.79	-0.71	-0.91	-0.68	-0.36	-0.84	-0.86	0.54		-0.95	-0.75	-0.88	-0.87	-0.89	-0.76	-0.94	-0.88	-0.25	-0.86	-0.79	-0.98	-0.94	-0.61	-0.91	-0.76	-0.95
Accounts Payable	0.76	0.73	0.86	0.67	0.48	0.82	0.76	-0.55	-0.95		0.74	0.78	0.78	0.8	0.76	0.88	0.82	0.18	0.77	0.77	0.97	0.87	0.69	0.8	0.75	0.9
Cash	0.96	0.26	0.86	0.96	0.62	0.98	0.83	-0.96	-0.75	0.74		0.83	0.76	0.77	0.97	0.82	0.58	0.27	0.62	0.84	0.79	0.81	0.8	0.79	0.97	0.8
Non Current Assets Total	0.91	0.41	0.91	0.84	0.42	0.88	1.0	-0.7	-0.88	0.78	0.83		0.96	0.95	0.85	0.9	0.7	0.46	0.86	0.91	0.87	0.94	0.65	0.97	0.88	0.88
Non Currrent Assets Other	0.87	0.49	0.92	0.78	0.5	0.85	0.93	-0.62	-0.87	0.78	0.76	0.96		0.99	0.8	0.9	0.7	0.55	0.88	0.88	0.85	0.96	0.69	0.9	0.84	0.88
Other Assets	0.86	0.52	0.95	0.76	0.49	0.87	0.92	-0.62	-0.89	0.8	0.77	0.95	0.99		0.8	0.94	0.77	0.49	0.88	0.87	0.87	0.98	0.7	0.91	0.83	0.92
Cash And Short Term Investments	0.99	0.29	0.84	0.98	0.65	0.96	0.85	-0.91	-0.76	0.76	0.97	0.85	0.8	0.8		0.83	0.55	0.47	0.73	0.9	0.8	0.84	0.84	0.81	0.99	0.8
Common Stock Total Equity	0.86	0.63	0.95	0.75	0.49	0.91	0.88	-0.63	-0.94	0.88	0.82	0.9	0.9	0.94	0.83		0.89	0.37	0.9	0.81	0.92	0.98	0.74	0.92	0.83	1.0
Common Stock Shares Outstanding	0.57	0.66	0.84	0.43	0.15	0.7	0.69	-0.35	-0.88	0.82	0.58	0.7	0.7	0.77	0.55	0.89		0.02	0.74	0.59	0.84	0.84	0.45	0.79	0.54	0.92
Short Term Investments	0.49	0.16	0.3	0.48	0.48	0.35	0.43	-0.25	-0.25	0.18	0.27	0.46	0.55	0.49	0.47	0.37	0.02		0.65	0.5	0.23	0.45	0.49	0.36	0.49	0.32
Non Current Liabilities Total	0.77	0.65	0.79	0.66	0.41	0.74	0.84	-0.42	-0.86	0.77	0.62	0.86	0.88	0.88	0.73	0.9	0.74	0.65		0.76	0.83	0.91	0.62	0.88	0.73	0.88
Other Current Assets	0.91	0.24	0.87	0.87	0.49	0.87	0.9	-0.77	-0.79	0.77	0.84	0.91	0.88	0.87	0.9	0.81	0.59	0.5	0.76		0.8	0.87	0.73	0.84	0.89	0.79
Other Stockholder Equity	0.82	0.71	0.9	0.73	0.42	0.86	0.85	-0.59	-0.98	0.97	0.79	0.87	0.85	0.87	0.8	0.92	0.84	0.23	0.83	0.8		0.92	0.64	0.88	0.8	0.93
Total Liab	0.88	0.58	0.97	0.78	0.49	0.91	0.91	-0.64	-0.94	0.87	0.81	0.94	0.96	0.98	0.84	0.98	0.84	0.45	0.91	0.87	0.92		0.73	0.93	0.86	0.98
Deferred Long Term Liab	0.83	0.4	0.73	0.82	0.93	0.85	0.62	-0.78	-0.61	0.69	0.8	0.65	0.69	0.7	0.84	0.74	0.45	0.49	0.62	0.73	0.64	0.73		0.6	0.85	0.72
Property Plant And Equipment Gross	0.85	0.47	0.88	0.77	0.32	0.85	0.98	-0.62	-0.91	0.8	0.79	0.97	0.9	0.91	0.81	0.92	0.79	0.36	0.88	0.84	0.88	0.93	0.6		0.81	0.9
Total Current Assets	1.0	0.31	0.86	0.99	0.69	0.97	0.87	-0.92	-0.76	0.75	0.97	0.88	0.84	0.83	0.99	0.83	0.54	0.49	0.73	0.89	0.8	0.86	0.85	0.81		0.81
Common Stock	0.83	0.66	0.95	0.72	0.47	0.9	0.85	-0.6	-0.95	0.9	0.8	0.88	0.88	0.92	0.8	1.0	0.92	0.32	0.88	0.79	0.93	0.98	0.72	0.9	0.81

Click cells to compare fundamentals

Cue Biopharma Account Relationship Matchups

Cue Biopharma fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	99.5M	83.4M	91.3M	61.5M	70.8M	66.4M
Other Current Liab	(2.0M)	333.6K	3.6M	4.1M	4.8M	5.0M
Total Current Liabilities	16.3M	12.8M	11.5M	17.1M	19.6M	10.1M
Total Stockholder Equity	78.9M	65.5M	65.7M	37.1M	42.6M	51.3M
Net Tangible Assets	54.6M	78.9M	65.5M	65.7M	75.5M	52.6M
Property Plant And Equipment Net	8.9M	11.9M	10.7M	7.1M	8.2M	6.4M
Net Debt	(67.7M)	(54.3M)	(32.3M)	(33.8M)	(30.4M)	(32.0M)
Retained Earnings	(153.3M)	(197.4M)	(250.5M)	(301.2M)	(271.1M)	(257.5M)
Accounts Payable	2.1M	2.6M	2.7M	3.5M	4.0M	4.2M
Cash	74.9M	64.4M	51.6M	48.5M	55.8M	47.6M
Non Current Assets Total	12.0M	14.9M	14.1M	10.1M	11.6M	8.6M
Non Currrent Assets Other	3.0M	2.9M	3.2M	2.8M	3.2M	2.1M
Other Assets	3.4M	3.1M	3.0M	3.4M	3.9M	2.1M
Cash And Short Term Investments	84.9M	64.4M	76.3M	48.5M	55.8M	54.1M
Common Stock Total Equity	26.6K	30.4K	32.2K	43.0K	49.5K	26.3K
Common Stock Shares Outstanding	28.7M	31.3M	35.6M	45.8M	52.6M	30.0M
Liabilities And Stockholders Equity	99.5M	83.4M	91.3M	61.5M	70.8M	66.4M
Non Current Liabilities Total	4.3M	5.1M	14.1M	7.4M	8.5M	5.1M
Other Current Assets	2.5M	1.8M	1.7M	1.2M	1.4M	1.2M
Other Stockholder Equity	232.2M	262.9M	316.2M	338.2M	389.0M	408.4M
Total Liab	20.6M	17.9M	25.6M	24.4M	28.1M	15.1M
Property Plant And Equipment Gross	8.9M	15.4M	14.9M	10.7M	12.3M	7.7M
Total Current Assets	87.5M	68.5M	77.2M	51.5M	59.2M	57.8M
Accumulated Other Comprehensive Income	(10.3K)	7.1K	0.0	(95.9K)	(110.3K)	(115.8K)
Common Stock	30.4K	32.2K	43.0K	47K	54.1K	29.1K
Property Plant Equipment	7.2M	2.1M	2.1M	1.5M	1.7M	2.6M
Non Current Liabilities Other	5.4M	4.3M	5.1M	6.0M	6.9M	4.8M
Short Long Term Debt Total	7.1M	10.1M	19.3M	14.7M	16.9M	10.9M
Current Deferred Revenue	4.1M	6.7M	645.3K	2.1M	2.4M	3.0M
Net Receivables	1.4M	3.1M	57.3K	1.7M	2.0M	1.5M
Net Invested Capital	78.9M	65.5M	75.7M	45.3M	52.0M	65.7M
Net Working Capital	71.2M	55.7M	65.6M	34.4M	30.9M	42.3M
Short Term Debt	9.6M	9.9M	5.3M	7.3M	8.4M	7.1M
Retained Earnings Total Equity	(108.5M)	(153.3M)	(197.4M)	(250.5M)	(225.4M)	(236.7M)
Capital Surpluse	163.1M	232.2M	262.9M	316.2M	363.6M	237.6M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

NVDA	NVIDIA
CRESY	Cresud SACIF y
GOOG	Alphabet Inc Class C

When determining whether Cue Biopharma is a strong investment it is important to analyze Cue Biopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cue Biopharma's future performance. For an informed investment choice regarding Cue Stock, refer to the following important reports:

How To Invest In Cue

Details

Is Cue Stock a good investment?

Details

What is Cue Biopharma's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cue Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.

For information on how to trade Cue Stock refer to our How to Trade Cue Stock guide.

You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cue Biopharma. If investors know Cue will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cue Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.91)

Revenue Per Share

0.172

Quarterly Revenue Growth

0.923

Return On Assets

(0.52)

Return On Equity

(1.39)

The market value of Cue Biopharma is measured differently than its book value, which is the value of Cue that is recorded on the company's balance sheet. Investors also form their own opinion of Cue Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Cue Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cue Biopharma's market value can be influenced by many factors that don't directly affect Cue Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Cue Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cue Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cue Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Cue Operating Income vs Tax Provision Analysis

Operating Income vs Tax Provision

Operating Income vs Tax Provision Correlation Analysis

Correlation Coefficient

Operating Income

Tax Provision

Cue Biopharma fundamental ratios Correlations

Cue Biopharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Cue Biopharma fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Common Stock	+ 1.0	Common Stock Total Equity
Cash And Short Term Investments	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Total Stockholder Equity
Other Assets	+ 0.99	Non Currrent Assets Other

Other Stockholder Equity	- 0.98	Retained Earnings
Cash	- 0.96	Net Debt
Common Stock	- 0.95	Retained Earnings
Accounts Payable	- 0.95	Retained Earnings
Total Liab	- 0.94	Retained Earnings
Common Stock Total Equity	- 0.94	Retained Earnings